Form 4: NextCure Director Elaine V. Jones Acquires Stock Options

Director Elaine V. Jones acquired stock options in NextCure, Inc. on June 20, 2024.

Summary

• Elaine V. Jones, a director of NextCure, Inc., reported a transaction involving derivative securities.
• On June 20, 2024, Jones acquired 18,700 stock options with an exercise price of $1.50.
• These options vest fully on the earlier of June 20, 2025, or the date of the 2025 Annual Meeting of Stockholders and expire on June 19, 2034.
• Following the transaction, Jones directly owns 18,700 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in executive compensation within the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies like NextCure.
• Companies such as Amgen, Gilead Sciences, and Biogen routinely grant stock options to align the interests of management with those of shareholders.
• The vesting schedule and exercise price are generally structured to incentivize long-term performance and retention.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates